What is Immunocore's gross profit margin?

What were the key takeaways from Immunocore’s earnings call?

What is the market's earnings forecast for Immunocore next quarter?

What is Immunocore's latest dividend and current dividend yield?

What were the key takeaways from Immunocore's earnings call?

What guidance did Immunocore's management provide for the next earnings period?

What factors drove the changes in Immunocore's revenue and profit?

What is the revenue and EPS growth rate for Immunocore year over year?

- **Revenue Surge**: 29% YoY growth to $400M, fueled by U.S. community adoption and global expansion.
- **Clinical Milestones**: 28-month OS in real-world data; TEBE-AM Phase III targeting 2026 readout for second-line melanoma.
- **Pipeline Momentum**: HIV program shows delayed viral rebound; Type 1 diabetes Phase I trial begins H1 2026.
- **Financial Strength**: $864M cash; 2026 growth expected to moderate to 4-7% QoQ.
- **Strategic Focus**: Defending KIMMTRAK's leadership in melanoma with OS data, expanding into cutaneous melanoma.

**【CEO Summary Section】**
- **Revenue Growth**: Full-year net revenue from KIMMTRAK reached $400 million, up 29% YoY, driven by U.S. community penetration and global expansion.
- **Clinical Impact**: Real-world data shows median overall survival of 28 months, with 14-month duration of therapy exceeding clinical trial results.
- **Pipeline Expansion**: Two Phase III trials (TEBE-AM in second-line cutaneous melanoma, ATOM in adjuvant uveal melanoma) on track for 2026 data. HIV functional cure program shows delayed viral rebound at higher doses.
- **Balance Sheet**: $864 million in cash, supporting pipeline advancement.

**【CFO Financial Commentary】**
- **Revenue Performance**: 2025 net sales $400 million (+29% YoY), with moderating growth expected in 2026 (4-7% QoQ growth).
- **Expense Management**: Operating loss reduced, with R&D and SG&A growth disciplined. 2026 R&D expenses to increase modestly.
- **Financial Flexibility**: Strong cash position ($864M) enables strategic investments.

**【Q&A Key Highlights】**
- **TEBE-AM Enrollment**: 85% European, 10-15% U.S., with control arm reflecting real-world treatments (checkpoint inhibitors, chemotherapy).
- **KIMMTRAK Pricing Strategy**: Data-dependent, aiming to defend price with OS endpoint in cutaneous melanoma.
- **HIV Program Progress**: Dose escalation ongoing, targeting viral reservoir impact. Phase I data expected H2 2026.
- **Autoimmune Initiative**: Type 1 diabetes Phase I trial set for H1 2026, targeting beta cell preservation without systemic immunosuppression.
- **Competitor Landscape**: Confident in KIMMTRAK's OS data vs. IDEYA's HLA-negative TCR-T, noting KIMMTRAK's 70% market penetration and real-world evidence.

Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 KIMMTRAK sales of $98 million (+30% YoY), with U.S. up 15% and Europe up 115%.
- **Pipeline Momentum**: Phase III trials (TEBE-AM, ATOM, PRISM-MEL) advancing; type 1 diabetes CTA expected by year-end 2025.
- **Financial Strength**: $883 million cash balance; net loss narrowed to $5 million (vs. $36 million in Q2 2024).
- **Strategic Expansion**: 28-country launch, 68% U.S. community prescriptions, and 13-month duration of therapy.
- **Innovation Focus**: Autoimmune programs and HIV viral control trials set to enter clinical testing in 2026.

**【CEO Summary Section】**
- Immunocore reported $192 million in KIMMTRAK revenue for the first half of 2025, a 32% year-over-year increase, driven by strong performance in the U.S. and Europe.
- The company emphasized three core pillars: maximizing KIMMTRAK's value, advancing clinical trials, and innovating for growth. Phase III trials in melanoma (TEBE-AM, ATOM, PRISM-MEL) are progressing, with TEBE-AM on track for enrollment completion in H1 2026.
- The pipeline includes autoimmune programs (type 1 diabetes, CD1a in atopic dermatitis) with a CTA expected for type 1 diabetes by year-end 2025.

**【Commercial Performance】**
- Q2 2025 net sales: $98 million (30% YoY growth), with U.S. contributing $64 million (15% YoY) and Europe $33 million (115% YoY growth).
- KIMMTRAK now launched in 28 countries, with 68% of U.S. prescriptions from community settings and a 13-month duration of therapy.
- Expansion into Turkey and MENA via Er-Kim partnership, and successful launches in the U.K., Poland, and Netherlands.

**【R&D Pipeline Updates】**
- **TEBE-AM (cutaneous melanoma):** Phase III trial with OS endpoint, enrolling well globally. IDMC will select the go-forward dose after 90 patients.
- **ATOM (adjuvant uveal melanoma):** Only Phase III trial in adjuvant setting, activated in Europe with U.S.启动计划 for fall 2025.
- **PRISM-MEL (first-line cutaneous melanoma):** Comparing brenetafusp doses vs. Opdualag, with 150 global sites activated.
- Early-stage programs: PRAME half-life extension, PIWIL in colorectal cancer, HIV viral control trials, and autoimmune candidate dosing set for 2026.

**【Financial Highlights】**
- Q2 2025 net loss: $5 million (vs. $36 million in Q2 2024), driven by 30% KIMMTRAK sales growth.
- R&D expenses increased due to Phase III trials and pipeline advancement; SG&A stable at $42 million/quarter.
- Cash balance: $883 million, supporting investments in clinical trials and pipeline expansion.
- Expect modest KIMMTRAK growth in 2025, with focus on life cycle management and new indications.

**【Q&A Key Highlights】**
- **TEBE-AM Design:** Control arm includes anti-PD-1 retreatment, reflecting real-world practice. IDMC will assess benefit-risk for dose selection.
- **Competitive Positioning:** KIMMTRAK is the #1 prescribed therapy in HLA-A*02:01+ uveal melanoma, with 22-month median OS vs. 12 months for competitors.
- **Autoimmune Strategy:** First clinical trial for type 1 diabetes planned for H1 2026, targeting tissue-specific PD-1 agonism.
- **FDA Interactions:** Trials designed with input from FDA; TEBE-AM and ATOM have sufficient U.S. sites and representative patient demographics.
- **Breakeven Expectation:** No timeline for profitability; focus on R&D investments and KIMMTRAK growth.


Immunocore Holdings plc (IMCR) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: $310M in 2024 (30% YoY), driven by U.S. KIMMTRAK expansion and global launches.
- **Pipeline Momentum**: 3 Phase III trials advancing, HIV Phase I data expected Q1 2025, and 2 autoimmune candidates entering clinic.
- **Financial Strength**: $820M cash, disciplined spending, and 30% R&D growth to fuel pipeline.
- **Strategic Focus**: Incremental KIMMTRAK growth, functional cure potential in HIV, and tissue-specific autoimmune therapies.


**【CEO Opening Remarks】**
- Immunocore achieved $310 million in 2024 revenue, up 30% YoY, driven by KIMMTRAK's 34% U.S. growth and global expansion into 24 countries.
- Highlighted progress in clinical pipeline: 3 Phase III trials (TEBE-AM, ATOM, PRISM-MEL) advancing, 2 Phase I trials initiated in infectious diseases, and 2 autoimmune candidates in development.
- Emphasized disciplined spending and strong balance sheet ($820M cash as of Q4 2024).

**【Ralph Torbay - KIMMTRAK Commercial Update】**
- Q4 2024 net sales: $84.1M (5% QoQ growth), full-year $310M (30% YoY).
- U.S. penetration: 65%, with 2/3 of new starts in community settings.
- Global expansion: 39 country approvals, including Brazil, and 80% market share in major markets.
- 2025 growth drivers: U.S. community expansion, therapy duration (>12 months), and ex-U.S. launches (UK, Poland).

**【David Berman - Pipeline Updates】**
- **Oncology**: 
  - TEBE-AM Phase III for second-line melanoma on track for 2026 data.
  - ATOM Phase III for adjuvant uveal melanoma enrolling globally.
  - PRAME-HLE Phase I in ovarian and lung cancer showing early signals.
- **Infectious Diseases**: 
  - HIV Phase I (STRIVE) MAD data to present in Q1 2025; HBV SAD data completed.
  - HIV target product profile: 20-30% viral control at 2 years.
- **Autoimmune**: 
  - S118 (T1D) and U120 (atopic dermatitis) on track for 2025 CTA submissions.

**【Travis Coy - Financial Highlights】**
- 2024 net sales: $310M (30% YoY), with 30% R&D spend growth due to clinical trial investments.
- 2025 outlook: KIMMTRAK incremental growth, R&D expansion for pipeline candidates.
- Cash position: $820M (end of 2024), supporting long-term strategy.

**【Q&A Key Takeaways】**
- **HIV Program**: 
  - STRIVE trial interim data (16 patients) to show viral reservoir reduction and rebound kinetics.
  - Potential for combination with LRAs if data supports functional cure.
- **Europe Sales Challenges**: 
  - Ongoing price negotiations in Germany and France; 14 successful global launches offset delays.
- **Brene Expansion**: 
  - Dose selection for PRISM-MEL Phase III based on 8-12 week follow-up; IDMC to evaluate safety and efficacy.
- **Autoimmune Safety**: 
  - Tissue-specific immune suppression (e.g., PD1 agonist tethered to target tissues) expected to avoid systemic effects.


Actual	-0.9297	-0.9	-0.4566	-0.1717	0.1365	-0.63	-0.43	-0.3693	0.0492	-0.4	-0.49	-0.23	0.17	-0.47	0.1	-0.2	-0.6
Forecast	-1.1236	-1.0763	-1.0972	-0.7324	-0.2784	0.0265	-0.3478	-0.3895	-0.3516	-0.2478	-0.368	-0.4759	-0.3431	-0.2264	-0.3798	-0.1372	-0.2117
Surprise	+17.26%	+16.38%	+58.38%	+76.56%	+149.03%	-2477.36%	-23.63%	+5.19%	+113.99%	-61.42%	-33.15%	+51.67%	+149.55%	-107.60%	+126.33%	-45.77%	-183.42%

IMCR

IMCR fundamentals

IMCR Q4 2025 Earnings

Earnings Call

You can ask Aime

IMCR

IMCR fundamentals

IMCR Q4 2025 Earnings

Earnings Call

IMCR Earnings Call Summary for Q4/20259:00 AM on Feb 25, 2026

IMCR Earnings Call Summary for Q2/20258:00 AM on Aug 7, 2025

IMCR Earnings Call Summary for Q1/20257:00 AM on May 7, 2025

IMCR Earnings Call Summary for Q4/20248:00 AM on Feb 26, 2025

IMCR Earnings Call Summary for Q3/2024 Apr 3, 2026

You can ask Aime